Acute Otitis Externa — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute otitis externa. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
4
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Acute Otitis Externa

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Fonseca Biosciences 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute otitis externa. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
30
1
31
1
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Xtoro
FINAFLOXACIN
 Fonseca Biosciences 4 64 — 2030-07-02

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9119859 Xtoro method of use 68 2030-07-02
8536167 Xtoro method of use 68 2031-08-08
9504691 Xtoro method of use 62 2033-11-21
9993483 Xtoro formulation 56 2030-07-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9993483 Xtoro formulation 56 2030-07-02
9504691 Xtoro method of use 62 2033-11-21
8536167 Xtoro method of use 68 2031-08-08
9119859 Xtoro method of use 68 2030-07-02

Related